Rights statement: This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Rheumatology following peer review. The definitive publisher-authenticated version Xueshan Bai, Mingshu Sun, Yuwei He, Ruhua Liu, Lingling Cui, Can Wang, Fang Wan, Ming Wang, Xinde Li, Hailong Li, Xinjiang Wu, Changgui Li, Serum CA72-4 is specifically elevated in gout patients and predicts flares, Rheumatology, 59 (10), 2020 https://doi.org/10.1093/rheumatology/keaa046 is available online at: https://academic.oup.com/rheumatology/article/59/10/2872/5748306
Accepted author manuscript, 1.95 MB, PDF document
Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License
Final published version
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Research output: Contribution to Journal/Magazine › Journal article › peer-review
}
TY - JOUR
T1 - Serum CA72-4 is specifically elevated in gout patients and predicts flares
AU - Bai, Xueshan
AU - Sun, Mingshu
AU - He, Yuwei
AU - Liu, Ruhua
AU - Cui, Lingling
AU - Wang, Can
AU - Wan, Fang
AU - Wang, Ming
AU - Li, Xinde
AU - Li, Hailong
AU - Wu, Xinjiang
AU - Li, Changgui
N1 - This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Rheumatology following peer review. The definitive publisher-authenticated version Xueshan Bai, Mingshu Sun, Yuwei He, Ruhua Liu, Lingling Cui, Can Wang, Fang Wan, Ming Wang, Xinde Li, Hailong Li, Xinjiang Wu, Changgui Li, Serum CA72-4 is specifically elevated in gout patients and predicts flares, Rheumatology, 59 (10), 2020 https://doi.org/10.1093/rheumatology/keaa046 is available online at: https://academic.oup.com/rheumatology/article/59/10/2872/5748306
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Objectives Serum CA72-4 levels are elevated in some gout patients but this has not been comprehensively described. The present study profiled serum CA72-4 expression in gout patients and verified the hypothesis that CA72-4 is a predictor of future flares in a prospective gout cohort. Methods To profile CA72-4 expression, a cross-sectional study was conducted in subjects with gouty arthritis, asymptomatic hyperuricaemia, four major arthritis types (OA, RA, SpA, septic arthritis) and healthy controls. A prospective gout cohort study was initiated to test the value of CA72-4 for predicting gout flares. During a 6-month follow-up, gout flares, CA72-4 levels and other gout-related clinical variables were observed at 1, 3 and 6 months. Results CA72-4 was highly expressed in patients with gouty arthritis [median (interquartile range) 4.55 (1.56, 32.64) U/ml] compared with hyperuricaemia patients [1.47 (0.87, 3.29) U/ml], healthy subjects [1.59 (0.99, 3.39) U/ml] and other arthritis patients [septic arthritis, 1.38 (0.99, 2.66) U/ml; RA, 1.58 (0.95, 3.37) U/ml; SpA, 1.56 (0.98, 2.85) U/ml; OA, 1.54 (0.94, 3.34) U/ml; P < 0.001, respectively]. Gout patients with frequent flares (twice or more in the last year) had higher CA72-4 levels than patients with fewer flares (fewer than twice in the last year). High CA72-4 level (>6.9 U/ml) was the strongest predictor of gout flares (hazard ratio = 3.889). Prophylactic colchicine was effective, especially for patients with high CA72-4 levels (P = 0.014). Conclusion CA72-4 levels were upregulated in gout patients who experienced frequent flares and CA72-4 was a useful biomarker to predict future flares.
AB - Objectives Serum CA72-4 levels are elevated in some gout patients but this has not been comprehensively described. The present study profiled serum CA72-4 expression in gout patients and verified the hypothesis that CA72-4 is a predictor of future flares in a prospective gout cohort. Methods To profile CA72-4 expression, a cross-sectional study was conducted in subjects with gouty arthritis, asymptomatic hyperuricaemia, four major arthritis types (OA, RA, SpA, septic arthritis) and healthy controls. A prospective gout cohort study was initiated to test the value of CA72-4 for predicting gout flares. During a 6-month follow-up, gout flares, CA72-4 levels and other gout-related clinical variables were observed at 1, 3 and 6 months. Results CA72-4 was highly expressed in patients with gouty arthritis [median (interquartile range) 4.55 (1.56, 32.64) U/ml] compared with hyperuricaemia patients [1.47 (0.87, 3.29) U/ml], healthy subjects [1.59 (0.99, 3.39) U/ml] and other arthritis patients [septic arthritis, 1.38 (0.99, 2.66) U/ml; RA, 1.58 (0.95, 3.37) U/ml; SpA, 1.56 (0.98, 2.85) U/ml; OA, 1.54 (0.94, 3.34) U/ml; P < 0.001, respectively]. Gout patients with frequent flares (twice or more in the last year) had higher CA72-4 levels than patients with fewer flares (fewer than twice in the last year). High CA72-4 level (>6.9 U/ml) was the strongest predictor of gout flares (hazard ratio = 3.889). Prophylactic colchicine was effective, especially for patients with high CA72-4 levels (P = 0.014). Conclusion CA72-4 levels were upregulated in gout patients who experienced frequent flares and CA72-4 was a useful biomarker to predict future flares.
KW - CA72-4
KW - biomarker
KW - gout
KW - flare
U2 - 10.1093/rheumatology/keaa046
DO - 10.1093/rheumatology/keaa046
M3 - Journal article
VL - 59
SP - 2872
EP - 2880
JO - Rheumatology
JF - Rheumatology
SN - 1462-0324
IS - 10
ER -